dc.contributor |
Medecins Sans Fronteres |
|
dc.creator |
Raguenaud, M E |
|
dc.creator |
Zachariah, R |
|
dc.creator |
Massaquoi, M |
|
dc.creator |
Ombeka, V |
|
dc.creator |
Ritter, H |
|
dc.creator |
Chakaya, J |
|
dc.date |
2008-10-22 |
|
dc.date.accessioned |
2017-01-31T07:12:40Z |
|
dc.date.available |
2017-01-31T07:12:40Z |
|
dc.identifier |
Global Public Health, Oct 2008 3(4): 433-439 |
|
dc.identifier |
http://hdl.handle.net/10144/39583 |
|
dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/39583 |
|
dc.identifier |
Global Public Health |
|
dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/39583 |
|
dc.description |
To access this article, click on "Additional Links". |
|
dc.description |
We conducted a study among patients with tuberculosis (TB) attending two health facilities - a hospital and a slum health centre - in Nairobi, in order to: (a) assess adherence to anti-TB treatment; and (b) identify reasons for non-adherence. Urine Isoniazid (INH), used as a proxy for overall adherence, was detected in 142 (97%) (95% CI 92-99) of the 147 patients involved in the study. Five patients had no INH detected in urine and had run out of pills within the previous three days. The reasons included: not having enough pills to last until the next appointment date (1); and losing some pills (1). Anti-TB treatment adherence is high, and is reassuring information as Kenya plans to change to a superior first-line regimen based on rifampicin throughout the course of anti-TB treatment. Providing patients with a three-day "excess stock" of pills would provide a "safety net" for continued treatment. |
|
dc.language |
en |
|
dc.publisher |
Taylor & Francis |
|
dc.relation |
http://www.informaworld.com/openurl?genre=article&issn=1744-1692&volume=3&issue=4&spage=433 |
|
dc.rights |
Archived on this site with thanks to Taylor & Francis |
|
dc.title |
High adherence to anti-tuberculosis treatment among patients attending a hospital and slum health centre in Nairobi, Kenya |
|